MPT

The onset of MPT establishes itself within twenty to forty minutes as a growing visual brightness and a moderate body buzz. Colors begin to sharpen and saturate, edges become more defined, and surfaces acquire a subtle luminosity. A tingling warmth builds in the torso and extremities, accompanied by a mild increase in heart rate and a slight tension in the jaw. The transition from baseline is steady and confident — neither as abrupt as DMT-like compounds nor as gradual as the gentlest tryptamines.

Over the next thirty to sixty minutes, the visual effects develop to a moderate plateau. Surfaces display a gentle breathing quality and may show soft geometric patterning — repeating motifs that overlay textures without obscuring them. Colors become noticeably more vivid, particularly warm tones, which seem to glow with an inner light. Closed-eye visuals offer more complexity: structured geometric forms, flowing patterns of color, and occasional dreamlike imagery that shifts with thought and mood. The visual character sits comfortably between the crystalline precision of DET and the flowing organicism of psilocin-type compounds — balanced, moderate, and aesthetically pleasing.

The peak arrives around sixty to ninety minutes and holds for two to three hours. The headspace is moderately altered: thoughts are more associative and reflective than usual, and there is a gentle expansion of awareness that encourages contemplation without compelling it. Emotional tone is generally positive, with a mild euphoria and a sense of quiet wellbeing. Cognitive function is not significantly impaired — conversations are manageable, and the user retains a clear sense of their state and surroundings. The body feels comfortable and mildly stimulated, with a pleasant warmth and a moderate energy level.

The comedown is gradual and uncomplicated, the visual enhancement and altered headspace fading smoothly over one to two hours. The total duration is four to six hours. The afterglow is mild — a subtle brightness of mood and a residual visual clarity that may last a few hours. MPT is a middle-of-the-road tryptamine in the truest sense: moderate in duration, intensity, and character, offering a reliable and balanced psychedelic experience that neither overwhelms nor underwhelms.

Pharmacology

Mechanism of Action

MPT (N-methyl-N-propyltryptamine) is an unsubstituted tryptamine that belongs to the same structural class as DMT, DET, and DPT. Based on the established pharmacology of this class, it is expected to act as an agonist at the serotonin 5-HT2A receptor — the primary molecular target through which classical psychedelics produce their characteristic perceptual and cognitive effects .

Pharmacological Data Gap

Notably, no formal receptor binding studies, functional assays, or in vivo behavioral experiments have been published specifically for MPT. In their self-experimentation trials documented in TiHKAL, the Shulgins reported experiencing no perceptible effects from oral doses up to 20 mg — a finding that either reflects genuinely low oral potency or suggests that higher doses may be required to achieve threshold effects .

Structural Considerations

The N-methyl-N-propyl substitution pattern places MPT structurally between DMT (N,N-dimethyl) and DPT (N,N-dipropyl). Structure-activity relationship studies on substituted tryptamines suggest that N-alkyl chain length has relatively modest effects on 5-HT2A binding affinity for unsubstituted tryptamines, though it may influence factors such as oral bioavailability, metabolic stability, and the subjective character of effects .

Crystal Structure

Chadeayne et al. (2019) solved the crystal structure of MPT, contributing to the physicochemical characterization of this compound and providing a structural reference for drug formulation research .

References

1. Rickli A, et al. Pharmacologic activity of substituted tryptamines at 5-HT2AR, 5-HT2CR, 5-HT1AR, and SERT. J Pharmacol Exp Ther. 2024;388(1):275-286.
2. Shulgin A, Shulgin A. TiHKAL: The Continuation. Transform Press, 1997.
3. Chadeayne AR, et al. N-Methyl-N-propyltryptamine (MPT). IUCrData. 2019;4:x190979.

History

MPT (N-methyl-N-propyltryptamine) was first synthesized and characterized by Alexander and Ann Shulgin and documented in their 1997 reference work TiHKAL: The Continuation. The Shulgins prepared it using their standard approach: reaction of indoleglyoxyl chloride with methylpropylamine to form the intermediate amide, followed by lithium aluminum hydride (LAH) reduction to yield the free tryptamine .

The compound attracted minimal attention in the years following publication. Its first appearance in the peer-reviewed literature outside of TiHKAL came in 2019, when Chadeayne et al. published its single-crystal X-ray diffraction structure in IUCrData, providing precise molecular geometry data . MPT has since appeared sporadically in novel psychoactive substance surveillance reports.

References

1. Shulgin A, Shulgin A. TiHKAL: The Continuation. Transform Press, 1997.
2. Chadeayne AR, et al. N-Methyl-N-propyltryptamine (MPT). IUCrData. 2019;4:x190979.